Glycoprotein News and Research

RSS

Experimental two‑in‑one vaccine shows success in human LASSARAB trial

Researchers from Thomas Jefferson University and the University of Maryland School of Medicine have reported encouraging results from the first human clinical trial of LASSARAB, an experimental vaccine designed to protect against Lassa fever and rabies in a single formulation.

9 Jun 2026

Study shows how HIV leads to chronic pain

Over half of the people carrying HIV experience chronic pain at some point, which is difficult to treat. In a new JNeurosci paper, Hui-Lin Pan, from The University of Texas MD Anderson Cancer Center, and colleagues used mice to explore how HIV leads to chronic pain.

1 Jun 2026

Scientists uncover shared gene signatures that reveal how mammals age

Researchers mapped more than 11,000 transcriptomes across mice, rats, macaques, and humans, revealing conserved molecular signatures of aging and mortality across tissues, species, and cell types. The study developed interpretable transcriptomic clocks that track age, mortality-related molecular change, chronic disease signals and responses to lifespan-altering interventions.

29 May 2026

New computational pipeline improves effectiveness of pan-Ebola neutralizing antibodies

A team led by Professor Wei Yang at the National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, has developed a computational-experimental pipeline that synergistically optimizes antibody framework regions (FR) and complementarity-determining regions (CDR).

24 May 2026

Blood metabolite patterns could reveal dementia risk in midlife

Research shows that blood metabolite profiles can indicate dementia risk, offering a potential tool for early detection and prevention of cognitive decline.

18 May 2026

Antibodies targeting GPNMB may slow Parkinson's disease progression

Monoclonal antibodies can block a key immune‑related protein that drives the spread of brain cell damage in Parkinson's disease (PD).

12 May 2026

New nanoparticles disable drug resistance to achieve complete tumor elimination

Cancer cells frequently develop the ability to expel anticancer drugs before they can work -- a phenomenon called multidrug resistance (MDR) -- which is one of the leading reasons why chemotherapy fails in patients.

8 May 2026

Pretargeted radioimmunotherapy shows promise for colorectal cancer treatment

A new pretargeted radioimmunotherapy (PRIT) technique has been shown to be safe and effective in eradicating tumors from a preclinical colorectal cancer model.

30 Apr 2026

Real-world study examines cangrelor dosing for antiplatelet bridging after PCI

A multi-center retrospective cohort study examined how cangrelor has been used in real-world clinical practice around the time of surgery following percutaneous coronary intervention (PCI) and described differences in outcomes seen with different dosing approaches.

24 Apr 2026

Nanodisc technology improves study of viral proteins for vaccines

Viruses are masters at invading our cells thanks to specialized proteins that coat their surfaces. When scientists design vaccines, they often create versions of these viral surface proteins to study how our immune systems might respond.

11 Apr 2026

Novel mucosal vaccine offers broad protection against diverse influenza viruses

A novel vaccine platform has been developed to induce broad, protective immunity against numerous influenza virus infections, showing promise as an effective mucosal vaccine strategy, according to a study published by researchers in the Institute for Biomedical Sciences at Georgia State University.

3 Apr 2026

Collaboration advances EMA601 as potential first-in-class stroke therapy

Boehringer Ingelheim and the Lower Franconian biotech company EMFRET Analytics have signed a cooperation and license agreement for the preclinical development program of the GPVI‑blocking antibody EMA601.

30 Mar 2026

Study opens the door for future treatments for Sleeping Sickness

To survive in the human bloodstream, the African trypanosome parasite wears a "cloak" made of proteins known as a variant surface glycoprotein (VSG).

30 Mar 2026

CDC tracks SARS-CoV-2 BA.3.2 global rise and finds early signals in U.S. wastewater

CDC surveillance shows that the highly divergent SARS-CoV-2 variant BA.3.2 spread to at least 23 countries and was detected in U.S. travelers, patients, airplane wastewater, and wastewater samples across multiple states. The report highlights wastewater and traveler-based genomic surveillance as early warning tools while noting that BA.3.2 has immune-evasion potential but has not rapidly displaced other circulating lineages.

25 Mar 2026

Marburg virus enters human cells far more efficiently than Ebola

In a new study published in Nature, University of Minnesota researchers found that the Marburg virus, one of the world's deadliest pathogens with an average 73% fatality rate, is unusually efficient at getting inside human cells.

11 Mar 2026

New structural insights pave way for hantavirus vaccines

Hantaviruses, transmitted from rodents to people, have a death rate approaching 40%. They're found around the world, and because there are no approved vaccines or treatments, they're among the pathogens of highest concern for future pandemics.

27 Feb 2026

Developmental ANGPTL4 deficiency protects mice from colitis and tumors

A novel study using a mouse model has found that the absence of the angiopoietin-like 4 (ANGPTL4) protein during development triggers a long-lasting reprogramming of the immune system that protects against intestinal inflammation.

18 Feb 2026

Osteoprotegerin links bone metabolism to cardiovascular disease

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Osteoprotegerin (OPG), a glycoprotein in the tumor necrosis factor superfamily, regulates bone metabolism by suppressing the formation and activation of osteoclasts.

13 Feb 2026

New strategy harnesses pre-existing antiviral immunity to boost anti-tumor responses

Because many different types of cancer cells overexpress programmed death-ligand 1 (PD-L1), this cell surface protein is a major target of cancer immunotherapy.

11 Feb 2026

Computational method clarifies microbial signals in tumor sequencing

When scientists sequence tumor DNA, they typically find small amounts of genetic code from bacteria, viruses and fungi – microorganisms that, if actually present in tumor tissues, could influence how they grow, evade immunity or respond to treatment.

5 Feb 2026